Dynavax's Heplisav-B outperforms GSK shot in PhIII trial

Vaccine

Dynavax is touting Phase III data announced this week showing that its hepatitis B vaccine Heplisav-B bested the standard-of-care Engerix-B, marketed by GlaxoSmithKline ($GSK) and first approved in 1989.

Berkeley, CA-based Dynavax said its candidate demonstrated statistically significant higher seroprotection rates of 95% compared to 81% for the Engerix-B group. For the trial, dubbed HBV-23, investigators divided participants into an 18-to-39 age range, finding that 99% of people in that group who received Heplisav-B were seroprotected versus 93% in the Engerix-B arm. The other group, ages 40 to 70, showed seroprotection rates of 95% for Heplisav-B compared to 79% for Engerix-B.

Dynavax’s vaccine is administered in two doses one month apart versus Engerix-B’s regimen of three doses over 6 months, a fact that RBC Capital Market’s Simos Simeonidis has previously said could help the shot get a majority of a $270 million market upon approval.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Bell’s palsy occurred in 0.09% of the Heplisav-B participants in the HBV-23 trial versus a rate of 0.04% in the Engerix-B group. Investigators noted single cases each of alopecia areata, polymyalgia rheumatic and ulcerative colitis in the Heplisav-B arms, as well. The data bring the vaccine’s safety database to 14,238 participants, more than 10,000 of whom have received Heplisav-B.

The PDUFA date for Heplisav-B is Sept. 15, 2016.

- here’s the release

Related Article:
Analyst: Dynavax hep B vaccine positioned to grab market share from GSK's Engerix-B

Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.